Lilly Pre-Approval Spadework Includes Alzheimer’s Blood Test Development, Unbranded DTC Ads

Donanemab’s review delay will create more distance from Lilly’s direct-to-consumer advertising spotlighting its commitment to Alzheimer’s research. The company has also been supporting development of blood-based tools for early diagnoses, though they would not eliminate PET scans.